tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

SSY Group Gains Approval for New Pharmaceutical Products

Story Highlights
SSY Group Gains Approval for New Pharmaceutical Products

Elevate Your Investing Strategy:

An announcement from SSY Group ( (HK:2005) ) is now available.

SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two new chemical drugs: Tranexamic Acid and Sodium Chloride Injection, and Levocarnitine Oral Solution. These approvals mark significant advancements in the company’s product offerings, enhancing its position in the pharmaceutical market by addressing bleeding disorders and carnitine deficiency.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is engaged in creating medical solutions for various health conditions, with a market focus on drug production and registration in China.

Average Trading Volume: 11,720,126

Technical Sentiment Signal: Sell

Current Market Cap: HK$8.79B

See more insights into 2005 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1